This invention provides a method of treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the patient laquinimod as an add-on therapy to or in combination with interferon-β. This invention also provides a package and a pharmaceutical composition comprising laquinimod and interferon-β for treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with interferon-β in treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and interferon-β in the preparation of a combination for treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome.本發明提供一種治療患有多發性硬化症或出現臨床單一症候群之患者之方法，其包括向該患者投與拉喹莫德(laquinimod)作為干擾素-β之輔助性治療(add-on therapy)或與干擾素-β組合。本發明亦提供包含拉喹莫德與干擾素-β之包裝及醫藥組合物，以治療患有多發性硬化症或出現臨床單一症候群之患者。本發明亦提供拉喹莫德作為輔助性治療或與干擾素-β組合用於治療患有多發性硬化症或出現臨床單一症候群之患者。本發明進一步提供拉喹莫德及干擾素-β於製備用於治療患有多發性硬化症或出現臨床單一症候群患者之組合之用途。
